AbbVie Inc. Accrued Royalties, Current
AbbVie Inc. (ABBV) had Accrued Royalties, Current of $453.00 million as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Payables and Accruals › Accrued Liabilities, Current
us-gaap:AccruedRoyaltiesCurrent · last filed 2026-02-20
- 2025-12-31: Accrued Royalties, Current $453.00M.
- 2024-12-31: Accrued Royalties, Current $527.00M.
- 2023-12-31: Accrued Royalties, Current $360.00M.
- 2022-12-31: Accrued Royalties, Current $412.00M.
| Period end | Accrued Royalties, Current |
|---|---|
| 2025-12-31 | $453.00M 10-K · filed 2026-02-20 |
| 2024-12-31 | $527.00M 10-K · filed 2026-02-20 |
| 2023-12-31 | $360.00M 10-K · filed 2025-02-14 |
| 2022-12-31 | $412.00M 10-K · filed 2024-02-20 |
| 2021-12-31 | $661.00M 10-K · filed 2023-02-17 |
| 2020-12-31 | $483.00M 10-K · filed 2022-02-18 |
| 2019-12-31 | $324.00M 10-K · filed 2021-02-19 |
| 2018-12-31 | $304.00M 10-K · filed 2020-02-21 |
| 2017-12-31 | $514.00M 10-K · filed 2019-02-27 |
| 2016-12-31 | $434.00M 10-K · filed 2018-02-16 |
| 2015-12-31 | $411.00M 10-K · filed 2017-02-17 |
| 2014-12-31 | $821.00M 10-K · filed 2016-02-19 |
| 2013-12-31 | $443.00M 10-K · filed 2015-02-20 |
| 2012-12-31 | $398.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |